Join your colleagues at ACC.23 Together With WCC for a comprehensive overview of the latest developments in the field of HF. Over the past year, there have been numerous pharmacologic and device therapy breakthroughs in the treatment of patients with HF, including treatments for HF with preserved ejection fraction, hypertrophic cardiomyopathy and cardiac amyloidosis. Experts will bring attendees up to speed on these developments and focus on the recently updated AHA/ACC/HFSA Guideline for the Management of Heart Failure. Hear directly from pathway topic coordinator, Amrut Ambardekar, MD, FACC, and register today to join us in New Orleans.